Glomerular filtration rate in liver transplant for unresectable hepatoblastoma.

Pediatr Transplant

Division of Gastroenterology and Nutrition, Department of Pediatrics, Saint Justine Hospital, Montreal, QC, Canada.

Published: September 2020

Most children with hepatoblastoma manifest, at the time of LT, a decrease in renal function due to chemotherapy that could be further deteriorated by the use of calcineurin inhibitors. The purpose of this work was to examine the long-term follow-up of renal function in a cohort of children transplanted for unresectable hepatoblastoma. We present a retrospective observational study of 10 pediatric patients who received a LT for unresectable hepatoblastoma between 1996 and 2016. All patients included in this study were followed up on a regular basis and were assessed for GFR before transplantation and at least once a year during follow-up. All patients received standardized chemotherapy treatment for hepatoblastoma and immunosuppression according to hospital protocols. There was a marked decrease in GFR at the time of the LT in five patients presenting renal complications during the pretransplant cycles of chemotherapy. Three patients, one of them with prior kidney involvement, presented complications after LT, namely acute kidney failure and decrease in GFR. Those patients who presented with the lowest GFR at the time of LT eventually recovered renal function at levels similar to the rest of the group on follow-up. Chemotherapy-induced nephrotoxicity is a concern in patients treated for hepatoblastoma. Some individuals will develop low GFR after chemotherapy; therefore, strict follow-up is recommended, as low GFR may affect the doses of subsequent chemotherapy and immunosuppression. Stabilization of GFR levels and occasional improvement can be observed in the post-transplant period.

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13746DOI Listing

Publication Analysis

Top Keywords

unresectable hepatoblastoma
12
renal function
12
patients received
8
decrease gfr
8
gfr time
8
low gfr
8
patients
7
gfr
7
hepatoblastoma
6
chemotherapy
5

Similar Publications

Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion.

Mol Cancer

December 2024

Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Ministry of Education, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare and underinvestigated subtype of primary liver cancer in children, generally has a poor prognosis and greater aggressiveness. Histological diagnosis of cHCC-CCA is difficult because of its diverse components, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). cHCC-CCA shares some genetic alterations with HCC and CCA.

View Article and Find Full Text PDF
Article Synopsis
  • Collaboration among international pediatric oncology groups has led to improved survival rates for children undergoing liver transplantation (LT) for unresectable liver tumors, establishing LT as the standard care method.
  • Hepatoblastoma and hepatocellular carcinoma (HCC) are the primary types of liver cancers treated with LT, showing over 80% long-term survival rates for hepatoblastoma and better outcomes for HCC when compared to liver resection.
  • The development of living donor liver transplantation has enhanced waitlist outcomes, graft quality, and timing with chemotherapy, while ongoing research and a multidisciplinary approach are essential for advancing treatments for these rare pediatric malignancies.
View Article and Find Full Text PDF

Introduction: Hepatoblastoma is the most common malignant primary liver tumor in the pediatric population, accounting for 67% of cases in the United States. Surgical resection is the only curative treatment option; however, it can be performed in only 10% of patients with primary tumors. The two most common limitations for resection are the need for extensive resections and tumors in central locations.

View Article and Find Full Text PDF

The aim of this study was to assess the long-term results of liver transplantation (LT) in pediatric patients with unresectable hepatoblastoma (HB) or hepatocellular carcinoma (HCC) with special reference to the risk of tumor recurrence. We retrospectively analyzed data from 46 HB and 26 HCC patients who underwent LT between 1990 and 2022. In HCC patients, we compared outcomes depending on donor type.

View Article and Find Full Text PDF

Modern-era successful liver transplantation outcomes in children with hepatic undifferentiated embryonal sarcoma.

Pediatr Transplant

February 2024

Department of Pediatrics, Pediatric Liver Center, Digestive Health Institute and Section of Pediatric Gastroenterology, Hepatology & Nutrition, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.

Background: Hepatic undifferentiated embryonal sarcoma (HUES) is the third most common primary hepatic malignancy in children. If unresectable, liver transplantation (LT) is the only curative option. Historically, HUES LT outcomes were not favorable; however, modern-era data are lacking.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!